載入...
Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
Antibody-drug conjugates (ADC) represent a distinct family of chemoimmunotherapy agents. ADCs are composed of monoclonal antibodies conjugated to cytotoxic payloads via specialized chemical linkers. ADCs therefore combine the immune therapy with targeted chemotherapy. Due to the distinct biomarkers...
Na minha lista:
| 發表在: | J Hematol Oncol |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6734251/ https://ncbi.nlm.nih.gov/pubmed/31500657 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0786-6 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|